Trial Profile
A Randomized Phase III Study to Compare Arsenic Trioxide (ATO) Combined to ATRA and Idarubicin Versus Standard ATRA and Anthracyclines-based Chemotherapy (AIDA Regimen) for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 10 Aug 2022
Price :
$35
*
At a glance
- Drugs Arsenic trioxide (Primary) ; Cytarabine; Idarubicin; Mercaptopurine; Methotrexate; Methotrexate; Mitoxantrone; Tretinoin
- Indications Acute promyelocytic leukaemia
- Focus Therapeutic Use
- Acronyms APOLLO
- 04 Aug 2022 Planned End Date changed from 1 Mar 2025 to 1 Jan 2025.
- 04 Aug 2022 Planned primary completion date changed from 1 Jul 2022 to 1 Jan 2025.
- 04 Aug 2022 Status changed from recruiting to active, no longer recruiting.